Resources

Request a quote

or call us at (469) 786-6060

Conjugation and Labeling Procedures for Isothiocyanato Derivatives

  1. The preparation of DTPA coupled antibodies radiolabeled with metallic radionuclides: an improved method.

    D. J. Hnatowich, R. L. Childs, D. Lanteigne, A. Najafi, J. Immunol. Methods, 1983, 65, 147-157.

    Abstract from www.NCBI.gov

  2. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamido reagents, methods of analysis, and subsequent addition of metal ions.

    C. F. Meares, M. J. McCall, D. T. Reardan, D. A. Goodwin, C. I. Diamanti, McTigue Anal. Biochem. 1984, 142, 68-78.

    Abstract from www.NCBI.gov

  3. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin.

    S. Mirzadeh, M. W. Brechbiel R. W. Atcher, O. A. Gansow Bioconjugate Chem. 1990,1, 59-65.

    Abstract from www.NCBI.gov

  4. Macrocyclic chelates of radiometals for diagnosis and therapy.

    C. F. Meares, M. K. Moi, H. Diril, D. L. Kukis, M. J. McCall, S. V. Deshapnde, S. J. DeNardo, D. Snook, A. A. Epenetos Br. J. Cancer1990, Suppl. 10, 21-26.

    Abstract from www.NCBI.gov

  5. An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid.

    M. E. Izard, G. R. Boniface, K. L. Hardiman, M. W. Brechbiel, O. A. Gansow, K. Z. Walkers Bioconjugate Chem. 1992, 3, 346-350.

    Abstract from www.NCBI.gov

  6. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies.

    T. K. Nikula; M. J. Curcio; M. W. Brechbiel; O. A. Gansow; R. D. Finn; D. A. Scheinberg Nucl. Med. Biol. 1995, 22, 387-90.

    Abstract from www.NCBI.gov

  7. Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of indium-111-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenographs.

    L. Camera, S. Kinyua, K. Garmestani, L. H. Pai, M. W. Brechbiel, O. A. Gansow, C. H. Paik, I. Pastan, J. A. Carrasquillo Nucl. Med. Biol . 1993, 20, 955-62.

    Abstract from www.NCBI.gov

  8. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

    D. L. Kukis, S. J. DeNardo, G. L. DeNardo, R. T. O’Donnell, C. F. Meares J. Nucl. Med.1998, 39, 2105-2110.

    Abstract from www.NCBI.gov

  9. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

    I. Verel, G. W. M. Visser, R. Boellaard, O. C. Boerman, J. van Eerd, G. B. Snow, A. A. Lammertsma, G.A.M.S van Dongen J. Nucl. Med. 2003, 44, 1663-1670.

    Abstract from www.NCBI.gov

  10. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).

    L. Camera, S. Kinuya, K. Garmestani, M. W. Brechbiel, C. Wu, L. H. Pai, T. J. McMurry, O. A. Gansow, I. Pastan Eur. J. Nucl. Med.1994, 21, 640-646.

    Abstract from www.NCBI.gov

  11. Improved in vivo stability and tumor targeting of bismuth labeled antibody.

    C. L. Ruegg, W. T. Anderson-berg, M. W. Brechbiel, S. Mirzadeh, O. A. Gansow, M. Strand Cancer Res. 1990, 50, 4221-4226.

    Abstract from www.NCBI.gov

  12. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft bearing nude mice.

    I. Verel, G. W. M. Visser, R. Boellaard, O. C. Boerman, J. van Eerd, G. B. Snow, A. A. Lammertsma, G. A. M. S. van Dongen, J. Nucl. Med.2003, 44, 1663-1670

    Abstract from www.NCBI.gov

  13. Specific localization, gamma camera imaging and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871in SK-MEL-28 melanoma xenografts.

    F. T. Lee, A. Rigopoulos, C. Hall Cancer Res. 2001, 61, 4474-4482.

    Abstract from www.NCBI.gov

  14. Targeting primary human Ph+ B-cell precursor leukemia-engrafted SCID mice usning radiolabeled anti-CD19 monoclonal antibodies.

    P. Mitchell, F. T. Lee, C. Hall, A. Rigopoulos, F. E. Smyth, A. M. Hekman, G. M. van Schijndel, R. Powles, M. W. Brechbiel, A. M. Scott, J. Nucl. Med. 2003, 44, 1105-1112. (CHX)

    Abstract from www.NCBI.gov

  15. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.

    H. Kobayashi, C. Wu, M. K. Kim, C. H. Paik, J. A. Carrasquillo, M. W. Brechbiel, Bioconjugate Chem. 1999, 10, 103-111.

    Abstract from www.NCBI.gov

  16. Pharmacokinetics, dosimetry and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

    M. Miederer, M. R. McDevitt, G. Sgouros, K. Kramer, N. K. V. Cheung, D. A. Scheinberg, J. Nucl. Med. 2004, 45, 129-137.

    Abstract from www.NCBI.gov

  17. Comparison of 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-p-(bromoacetamido)benzyl-DOTA-ChL6 in breast cancer xenografts.

    G. L. DeNardo, L. A. Kroger, C. F. Meares, C. M. Richman, Q. Salako, S. Shen, K. R. Lamborn, J. J. Peterson, L. A. Miers, G. R. Zhong, S. J. DeNardo Clinical Cancer Research1998, 4, 2483-90.

    Abstract from www.NCBI.gov

  18. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent.

    M. J. Blend, J. J. Stastny, S. M. Swanson, M. W. Brechbiel Cancer Biotherapy & Radiopharmaceuticals2003, 18, 355-363.

    Abstract from www.NCBI.gov

  19. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

    T. K. Nikula, M. R. McDevitt, R. D. Finn, C. Wu, R. W. Kozak, K. Garmestani, M. W. Brechbiel, M. J. Curcio, C. G. Pippin; L. Tiffany-Jones, M. W. Sr. Geerlings, C. Apostolidis, R. Molinet, M. W. Jr. Geerlings, O. A. Gansow, D. A. Scheinberg J. Nucl. Med. 1999, 40, 166-76.

    Abstract from www.NCBI.gov

  20. Pretargeted alpha-emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetraacetic Acid-biotin.

    Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, I. Pastan, C. H. Paik, M. W. Brechbiel, J. A. Carrasquillo Clinical Cancer Research2004, 10, 3137-3146.

    Abstract from www.NCBI.gov

Application of DOTA-tris(tert-Bu) in the Synthesis of DOTA-peptides

  1. Solid-phase synthesis of DOTA-peptides.

    L. M. De Leon-Rodriguez, Z. Kovacs, G. R. Dieckmann, A. D. Sherry, Chem.Eur. J., 200410, 1149-1155.

    Abstract from www.NCBI.gov

  2. Magnetic resonance imaging detects a specific peptide-protein binding event.

    L. M. De León-Rodriguez, A. Ortiz, A. Weiner, S. Zhang, Z. Kovacs, T.J. Kodadek, A. D. Sherry, J. Am. Chem. Soc.2002, 124, 3514-3515.

    Abstract from www.NCBI.gov

  3. Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat derived membrane translocation peptide.

    R. Bhorade, R. Weissleder, T. Nakakoshi, A. Moore, C.-H. Tung Bioconjugate Chem. 2000, 11, 301-305.

    Abstract from www.NCBI.gov

  4. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.

    T. J. Hoffman, H. Gali, C. J. Smith, G. L. Sieckman, D. L. Hayes, N. K. Owen, W. A. Volkert J. Nucl. Med. 2003, 44, 823-831.

    Abstract from www.NCBI.gov

  5. Poly(L-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging.

    Z. R. Lu, X. Wang, D. L. Parker, K. C. Goodrich, H. R. Buswell Bioconjugate Chem. 2003, 14, 715-719.

    Abstract from www.NCBI.gov

  6. Chemical synthesis of Escherichia Coli ST h analogues by regioselectivedisulfide bond formation: biological evaluation of an 111In-DOTA-Phe 19-ST h analogue for specific targeting of human colon cancers.

    H. Gali, G. L. Sieckman, T. J. Hoffman, N. K. Owen, D. G. Mazuru, L. R. Forte, W. A. Volkert, Bioconjugate Chem. 2002, 13, 224-231.

    Abstract from www.NCBI.gov

  7. Evaluation of cleavable (Tyr 3)-octreotate derivatives for longer intracellular probe residence.

    P. A. Whetstone, H. Akizawa, C. F. Meares, Bioconjugate Chem . 2004, 15, 647-657.

    Abstract from www.NCBI.gov

  8. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy.

    A. Heppeler, S. Froidevaux, H. R. Maecke, E. Jermann, M. Behe, P. Powell, M. Hennig, Chem. Eur. J.1999, 5, 1974-1981. (DOTA-tris-tBu)

    Abstract from www.NCBI.gov

Coupling with DOTA and Activated Esters of DOTA

  1. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinidyl DOTA.

    M. R. Lewis, J. Y. Kao, A. L. Anderson, J. E. Shively, A. Raubitschek, Bioconjugate Chem . 2001, 12, 320-324.

    Abstract from www.NCBI.gov

  2. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.

    L. Li, S. W. Tsai, A.-L. Anderson, D. A. Keire, A. A. Raubitschek, J. E. Shively; Bioconjugate Chem. 2002, 13, 110-115.

    Abstract from www.NCBI.gov

  3. MicroPET and autoradiographic imaging of breast cancer a V-integrin expression using 18F- and 64Cu-labeled RGD peptide.

    X. Chen, R. Park, M. Tohme, A. H. Shahinian, J. R. Bading, P. S. Conti Bioconjugate Chem. 2004, 15, 41-49.

    Abstract from www.NCBI.gov

  4. Conformation and structure of polymeric contrast agents for medical imaging.

    E. E. Uzgiris, H. Cline, B. Moasser, B. Grimmond, M. Amaratunga, J. F. Smith, G. Goddard, Biomacromolecules2004, 5, 54-61.

    Abstract from www.NCBI.gov

  5. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker.

    W. Mier, J. Hoffend, S. Kramer, J. Schuhmacher, W. E. Hull, M. Eisenhut, U. Haberkorn Bioconjugate Chem . 2005, 16, 237?-240

    Abstract from www.NCBI.gov

  6. Direct synthesis of DOTA-DPhe 1-octreotide and DOTA-DPhe 1, Tyr 3-octreotide (SMT487): Two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.

    R Albert, P. Smith-Jones, B. Soltz, C. Simeon, H. Knecht, C. Bruns, J. Pless Bioorg. Med. Chem. Lett. 1998, 8, 1207 -1210.

    Abstract from www.NCBI.gov

TmDOTP as an in vivo Temperature Probe

  1. Brain temperature measured by 1H-NMR in conjunction with a lanthanide complex.

    H. K. F. Trubel, P. K. Maciejewski, J. H. Farber, F. Hyder J. Appl. Physiol. 2003, 94, 1641-1649.

    Abstract from www.NCBI.gov

  2. Simultaneous measurements of temperature and pH in Vivo using NMR in conjuction with TmDOTP5-.

    Y. Sun, M Sugawara, R. V. Mulkern, K. Hynyen, S. Mochizuki, M. Albert, C. S. Zuo, NMR Biomed. 2000, 13, 460-466.

    Abstract from www.NCBI.gov